Regeneron Pharmaceuticals, Inc. - REGN
About Gravity Analytica
Recent News
- 06.13.2025 - 2025 Annual Meeting of Shareholders
- 04.29.2025 - Regeneron Pharmaceuticals Q1 2025 Earnings Conference Call
- 04.29.2025 - Regeneron Pharmaceuticals Q1 2025 Earnings Conference Call
- 04.22.2025 - Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines
- 04.21.2025 - Regeneron Announces Investor Conference Presentations
- 04.18.2025 - Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application
- 04.18.2025 - Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
- 04.17.2025 - EYLEA HD® (aflibercept) Injection 8 mg sBLA Accepted for FDA Priority Review for Both the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing in Approved Indications
- 03.28.2025 - Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)
- 03.25.2025 - Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025